BIOMAT Database Logo BIOMAT Database Logo

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. 1997

M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Merck Research Laboratories, West Point, PA 19486, USA.

We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy male subjects. DuP 532 (1 to 200 mg) was well tolerated, with no effect on blood pressure or heart rate. Compared with losartan (100 mg), DuP 532 (200 mg) was a weak antagonist of pressor responses to intravenous angiotensin II. Maximum inhibition of diastolic pressor response was 86% (95% confidence interval [CI], 84%, 88%) approximately 4.6 hours after losartan and 48% (95% CI, 38%, 56%) 8.7 hours after DuP 532. Twenty-four hours after dosing, inhibition by losartan and DuP 532 was similar (40% to 45%). DUP 532 is extensively bound in human plasma, with an in vitro free fraction of 0.06. Although DuP 532 and EXP3174 (losartan's active metabolite) have similar AT1-receptor potency, and plasma concentrations of DuP 532 were much greater than losartan/EXP3174, the level of antagonism was much less for DuP 532. These results indicate that multiple factors determine the in vivo potency of angiotensin II antagonists, including affinity for and distribution to the receptor as modulated by plasma binding.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl

Related Publications

M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Renin release induced by losartan (DuP 753), an angiotensin II receptor antagonist.
January 1993, Clinical and experimental hypertension (New York, N.Y. : 1993),
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
[Losartan potassium, an angiotensin II receptor antagonist].
February 2000, Nihon rinsho. Japanese journal of clinical medicine,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Discovery of losartan, the first angiotensin II receptor antagonist.
November 1995, Journal of human hypertension,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Angioedema associated with angiotensin II receptor antagonist losartan.
May 1997, Southern medical journal,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists.
May 1991, Biochemical and biophysical research communications,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
January 1996, Blood pressure. Supplement,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
[Losartan: angiotensin II type 1 receptor antagonist].
January 1999, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs.
January 1994, Biopharmaceutics & drug disposition,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
September 1992, The Journal of pharmacology and experimental therapeutics,
M R Goldberg, and M W Lo, and D D Christ, and R Chiou, and C I Furtek, and O Amit, and A Carides, and J Biollaz, and V Piguet, and J Nussberger, and H R Brunner
Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist.
April 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Copied contents to your clipboard!